Targeted drug discovery and development
Allows companies to do 1000x more testing for the same spend
Facilitating combination therapy for better disease management
Provides a robust, time-effective platform for personalised medicine
Despite ongoing efforts toward finding novel entities for the treatment of the most challenging cancers, translation into patient benefit has been slow due to the fact that translational cancer research from early drug discovery to late stage drug development and assessment in clinical trials is a long process.
Our microfluidic platform delivers precise control over the cellular microenvironment and beneficially through miniaturization, maximizes use of precious limited human cancer samples.
Immense possibilities for testing patient-derived multicellular tumor spheroids/organoids for disease/biomarker-oriented drug activity and profiling using single- and pair-wise standard/targeted drug combinations
In the area of personalized medicine, it is highly pertinent to not only predict the drug response at early time points during the therapy, but also to be able to identify the optimal drug combination for an individual patient.
This approach has the potential to identify individualized optimal therapy whilst providing cost and time effective options to relevant stakeholders for better health-care delivery.